Adenosine protects cultured retinal neurons against NMDA-induced cell death through A1 receptors

Current Eye Research

Volumn 29, Issue 6, 2004, Pages 449-455

  Oku, Hidehiro ^a,d   Goto, Wakana ^a   Kobayashi, Takatoshi ^a   Okuno, Takashi ^a   Hirao, Mami ^a   Sugiyama, Tetsuya ^a   Yoneda, Shinji ^b   Hara, Hideaki ^c   Ikeda, Tsunehiko ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

A1 and A2a receptors; Adenosine; Cultured retinal neurons; N methyl D aspartate; Rat

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 6 N [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; 8 BROMO CYCLIC AMP; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FETUS; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA AMACRINE CELL; RETINA NERVE CELL;

ADENOSINE; ANIMALS; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; COLORING AGENTS; CYTOPROTECTION; EXCITATORY AMINO ACID AGONISTS; FEMALE; N-METHYLASPARTATE; NEUROGLIA; PREGNANCY; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A1; RETINA; TRYPAN BLUE;

EID: 6944256462     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680490522443     Document Type: Article

References (50)

1. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev. 1992;4:346-369.
2. Rudolphi KA, Schubert P. Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Behav Brain Res. 1997;83:123-128.
3. Phillis JW. Adenosine in the control of the cerebral circulation. Cerebrovasc Brain Metab Rev. 1989;1:26-54.
4. Wardas J. Neuroprotective role of adenosine in the CNS. Pol J Pharmacol. 2002;54:313-326.
5. Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann NY Acad Sci. 1999;890:79-92.
6. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc Natl Acad Sci U S A. 1995;92:4666-4670.
7. Roth S, Li B, Rosenbaum PS, Gupta H, Goldstein IM, Maxwell KM, Gidday JM. Preconditioning provides complete protection against retinal ischemic injury in rats. Invest Ophthalmol Vis Sci. 1998;39:777-785.
8. Lin J, Roth S. Ischemic preconditioning attenuates hypoperfusion after retinal ischemia in rats. Invest Ophthalmol Vis Sci. 1999;40:2925-2931.
9. Li B, Yang C, Rosenbaum DM, Roth S. Signal transduction mechanisms involved in ischemic preconditioning in the rat retina in vivo. Exp Eye Res. 2000;70:755-765.
10. Macaluso C, Frishman LJ, Frueh B, Kaelin-Lang A, Onoe S, Niemeyer G. Multiple effects of adenosine in the arterially perfused mammalian eye. Possible mechanisms for the neuroprotective function of adenosine in the retina. Doc Ophthalmol. 2003;106:51-59.
11. Toprak AB, Ozbilgin K, Toprak V, Tuglu I, Guler C. A histological analysis of the protective effect of ischemic preconditioning in the rat retina. Curr Eye Res. 2002;24:234-239.
12. Zhang C, Rosenbaum DM, Shaikh AR, Li Q, Rosenbaum PS, Pelham DJ, Roth S. Ischemic preconditioning attenuates apoptotic cell death in the rat retina. Invest Ophthalmol Vis Sci. 2002;43:3059-3066.
13. Ettaiche M, Heurteaux C, Blondeau N, Borsotto M, Tinel N, Lazdunski M. ATP-sensitive potassium channels (K(ATP)) in retina: A key role for delayed ischemic tolerance. Brain Res. 2001;890:118-129.
14. Li B, Roth S. Retinal ischemic preconditioning in the rat: Requirement for adenosine and repetitive induction. Invest Ophthalmol Vis Sci. 1999;40:1200-1216.
15. Zhang WL, Lu GW. Changes of adenosine and its A(1) receptor in hypoxic preconditioning. Biol Signals Recept. 1999;8:275-280.
16. Roth S, Rosenbaum PS, Osinski J, Park SS, Toledano AY, Li B, Moshfeghi AA. Ischemia induces significant changes in purine nucleoside concentration in the retinachoroid in rats. Exp Eye Res. 1997;65:771-779.
17. Roth S, Park SS, Sikorski CW, Osinski J, Chan R, Loomis K. Concentrations of adenosine and its metabolites in the rat retina/choroids during reperfusion after ischemia, Curr Eye Res. 1997;16:875-885.
18. Dunwiddie TV, Fredholm BB. Adenosine A1 receptors inhibit adenylate cyclase activity and neurotransmitter release and hyperpolarize pyramidal neurons in rat hippocampus. J Pharmacol Exp Ther. 1989;249:31-37.
19. Reshef A, Sperling O, Zoref-Shani E. Opening of K(ATP) channels is mandatory for acquisition of ischemic tolerance by adenosine. Neuroreport. 2000;11:463-465.
20. Fredholm BB, Duner-Engstrom M. Propentofylline and a hydroxy metabolite augment A2-receptor mediated cyclic AMP accumulation and attenuate A1-receptor mediated inhibition of acetylcholine release in the rat hippocampus. Pharmacol Toxicol. 1989;65:347-351.
21. Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol. 1996;48:167-189.
22. Larsen AK, Osborne NN. Involvement of adenosine in retinal ischemia. Studies on the rat. Invest Ophthalmol Vis Sci. 1996;37:2603-2611.
23. Li B, Rosenbaum PS, Jennings NM, Maxwell KM, Roth S. Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat. Exp Eye Res. 1999;68:9-17.
24. Ferreira JM, Paes-de-Carvalho R. Long-term activation of adenosine A(2a) receptors blocks glutamate excitotoxicity in cultures of avian retinal neurons. Brain Res. 2001;900:169-176.
25. Haik GM Jr, Terrell WL 3rd, Haik GM Sr. Diabetic retinopathy: A leading cause of new blindness. South Med J. 1989;82:575-579.
26. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996;80:389-393.
27. Ambati J, Chalam KV, Chawla DK, D'Angio CT, Guillet EG, Rose SJ, Vanderlinde RE, Ambati BK. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1997;115:1161-1166.
28. Brooks DE, Garcia GA, Dreyer EB, Zurakowski D, Franco-Bourland RE. Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res. 1997;58:864-867.
29. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
30. Osborne NN, Ugarte M, Chao M, Chidlow G, Bae JH, Wood JP, Nash MS. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43(Suppl 1):102-128.
31. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997;37:3483-3493.
32. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A. 1991;88:6368-6371.
33. Kwong JM, Lam TT. N-methyl-D-aspartate (NMDA) induced apoptosis in adult rabbit retinas. Exp Eye Res. 2000;71:437-444.
34. Lam TT, Abler AS, Kwong JM, Tso MO. N-methyl-D-aspartate (NMDA)-induced apoptosis in rat retina. Invest Ophthalmol Vis Sci. 1999;40:2391-2397.
35. Li Y, Schlamp CL, Nickells RW. Experimental induction of retinal ganglion cell death in adult mice. Invest Ophthalmol Vis Sci. 1999;40:1004-1008.
36. Manzoni OJ, Manabe T, Nicoll RA. Release of adenosine by activation of NMDA receptors in the hippocampus. Science. 1994;265:2098-2101.
37. Bhardwaj A, Northington FJ, Koehler RC, Stiefel T, Hanley DF, Traystman RJ. Adenosine modulates N-methyl-D-aspartate-stimulated hippocampal nitric oxide production in vivo. Stroke. 1995;26:1627-1633.
38. Kvanta A, Seregard S, Sejersen S, Kull B, Fredholm BB. Localization of adenosine receptor messenger RNAs in the rat eye. Exp Eye Res. 1997;65:595-602.
39. Kashii S, Takahashi M, Mandai M, Shimizu H, Honda Y, Sasa M, Ujihara H, Tamura Y, Yokota T, Akaike A. Protective action of dopamine against glutamate neurotoxicity in the retina. Invest Ophthalmol Vis Sci. 1994;35:685-695.
40. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984;307:462-465.
41. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527-552.
42. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413-492.
43. Yamauchi T, Kashii S, Yasuyoshi H, Zhang S, Honda Y, Akaike A. Mitochondrial ATP-sensitive potassium channel: A novel site for neuroprotection. Invest Ophthalmol Vis Sci. 2003;44:2750-2756.
44. Mayer ML, Miller RJ. Excitatory amino acid receptors, second messengers and regulation of intracellular Ca2+ in mammalian neurons. Trends Pharmacol Sci. 1990;11:254-260.
45. Lo EH, Bosque-Hamilton BAP, Meng W. Inhibition of poly (ADP-ribose) polymerase reduction of ischemic injury and attenuation of N-methyl-D-aspartate- induced neurotransmitter dysregulation. Stroke. 1998;29:830-836.
46. Sun X, Barnes S, Baldridge WH. Adenosine inhibits calcium channel currents via A1 receptors on salamander retinal ganglion cells in a mini-slice preparation. J Neurochem. 2002;81:550-556.
47. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13:2651-2661.
48. Feoktistov I, Biaggioni I. Adenosine A2B receptors. Pharmacol Rev. 1997;49:381-402.
49. Gidday JM, Maceren RG, Shah AR, Meier JA, Zhu Y. KATP channels mediate adenosine-induced hyperemia in retina. Invest Ophthalmol Vis Sci. 1996;37:2624-2633.
50. Polska E, Ehrlich P, Luksch A, Fuchsjager-Mayrl G, Schmetterer L. Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans. Invest Ophthalmol Vis Sci. 2003;44:3110-3114.